LMNA related cardiac diseases information and network
On the 10th of October 2022 the LMNA Cardiac Foundation is organizing an international LMNA Patient Meeting together with the Netherlands Heart Institute. This webinar will have a focus on patients but family, experts are ofcourse more than welcome too. This is a free online webinar with some very interesting speakers. Agenda: Date: October 10th, […]
Pfizer Inc. (NYSE: PFE) announced that an interim futility analysis of the global Phase 3 trial, REALM-DCM, designed to evaluate the efficacy and safety of PF-07265803 in patients with symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA), indicated the trial is unlikely to meet its primary […]
We are excited to announce the first DCM Patient and Family Conference, organized by the DCM Foundation, bringing hope and education to DCM patients and their family members. This full-day VIRTUAL event will be held from 11:00 AM – 5:00 PM EST and will be broken into 3 segments, each with Live Q&A. One registration […]
WEBINAR Date: July 20th, 2022 – 6:00-7:00 PM ET* (watch the recorded webinar) Details: Join us as we learn about the basics of DCM genetics and the future of DCM gene therapy. This promises to be a very interesting and informative event for all DCM patients and their family members. Topics Include: Basics of DCM Genetics […]
The 2022 inaugural Global Heart Hub Cardiomyopathy Awareness Week Campaign aims to improve awareness, diagnosis and management of cardiomyopathy. The 2022 campaign theme is ‘Get to the heart of it’. The awareness campaign is led by the Cardiomyopathy Patient Council of the Global Heart Hub. The Cardiomyopathy Patient Council was formed in November 2021 and […]
During this webinar; critical information regarding genetic components of dilated cardiomyopathy, and Pfizer’s exciting Phase 3 Clinical Trial for which they are recruiting patients with the LMNA variant. Topics of the webinar include: – Genetics and progressive stages of DCM – Diagnosis, Evaluation of Family Disease Risk, and Treatment – Explanation of Pfizer’s Phase 3 […]
Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as its initiating director of operations have announced the closure of its seed investment round. This pre-seed investment will be used to advancePhlox’s lead program focused on rare […]
WEBINAR INVITATION Therapies & Hope for LMNA-related DCM Patients During this webinar, organized by DCM foundation, critical information regarding genetic components of dilated cardiomyopathy, and Pfizer’s exciting Phase 3 Clinical Trial for which they are recruiting patients with the LMNA variant will be shared. Topics of the webinar will include:– Genetics and progressive stages of […]
RECORDED LMNA RESEARCH MEETING Discovering a cure for LMNA: Current strategies, crazy ideas and future collaborations Dear Sir, Madam, Thank you for joining the Research meeting focused on Lamin A/C Cardiomyopathy last Wednesday, April 13, 2022. We enjoyed it a lot and hope you did as well! 1. RecordingWe are happy to share the full recording of the Zoom […]
LMNAcardiac.org is a new network for experts and patients focussed on LMNA cardiac diseases, with the aim of accelerating research and development to find effective treatments. The disease is caused by mutations in the LMNA gene, and is characterized by a high rate of major cardiac events caused by impaired contraction of the heart. Catalyze completed a Market […]
English
Dutch
French
German
Spanish